Clinical commissioning policy: Lanreotide as a monotherapy for the treatment of symptomatic non-localised autosomal dominant polycystic liver disease (adults)

Document first published:
Page updated:
Topic:
Publication type:

The off-label use of lanreotide is recommended to be available as a routine commissioning treatment option for autosomal dominant polycystic liver disease within the criteria set out in this document.

Document

Clinical commissioning policy: Lanreotide as a monotherapy for the treatment of symptomatic non-localised autosomal dominant polycystic liver disease (adults)

Clinical commissioning policy: Lanreotide as a monotherapy for the treatment of symptomatic non-localised autosomal dominant polycystic liver disease (adults)

  • PDF
  • 340 KB
  • 8 pages

Summary

Published 16 July 2026.